The activity of RSK2 has emerged as an attractive target for cancer therapy due to its role in the regulation of diverse cellular processes, such as cell transformation and proliferation and the maintenance of cancer stem cells (CSCs) [1]. This evidence concerns the gene RPS6KA3 and cancer.